Oncology Archives - Page 7 of 23

ESMO 2022: Advances in oncology

Earlier this month, 29,300 people took part in ESMO 2022. Although online attendance remained an option, thousands flocked to Paris, France to experience the action-packed program in-person for the first time since...

Cancer Inequity: What is it and what can be done?

What is the care gap? There are glaring differences that exist in cancer outcomes and access to care across regions and socioeconomic groups. These inequities amount to a gap in cancer care....

Cervical cancer screening guidelines and screening practices in 11 countries: a systematic literature review

Authors: W Wang, E Arcà, A Sinha, K Hartl, N Houwing, S Kothari Published: Preventative Medicine Reports, 2022 View publication Abstract The World Health Organization (WHO) advocates population-based screening programs to reduce...

Treatment patterns and outcomes among nontransplant newly diagnosed multiple myeloma patients in Spain

Authors: J-Á Hernández-Rivas, M Arnao, J M A Pérez, A Rubio, E G García, D de Miguel, D Cherepanov, D Romanus, K Verleger, C Johnson, S L Corman, M Grande, E P...

Major variation in hepatocellular carcinoma treatment and outcomes in England: a retrospective cohort study

Authors: S Beecroft, M O’Connell, A Nassar, K Noon, K G Pollock, D Palmer, T J S Cross Published: Frontline gastroenterology, 2022 View publication Objective Hepatocellular carcinoma (HCC) is increasingly incident in...

Implications of systemic adjuvant melanoma treatments for U.K. melanoma services: Results of the U.K. Melanoma Adjuvant Pathway Survey

Authors: O Cassell, C Harwood, M Hovey, M Payne Published: European Journal of Cancer Care, 2022 View publication Objective To understand current U.K. management pathways for patients with resected stage III melanoma...

Cost-effectiveness analysis of KTE-X19 CAR T therapy versus real-world standard of care in patients with relapsed/refractory mantle cell lymphoma post BTKi in England

Authors: Svenja Petersohn 1, Gilles Salles 2, Michael Wang 3, Jim Wu 4, Sally W Wade 5, Claire L Simons 6, Craig Bennison 6, Rubina Siddiqi 4, Weimin Peng 4, Ioana Kloos...

A quality-adjusted survival time without symptom or toxicities analysis of glasdegib plus low-dose cytarabine versus low-dose cytarabine as initial therapy for acute myeloid leukemia in patients who are not considered candidates for intensive chemotherapy

Authors: C T Solem, T J Bell, Y Kwon, J C Cappelleri, C Johnson, H Bhattacharyya, C J Hoang, J E Cortes Published: Cancer, 2020 View publication Background In a randomized study,...

A retrospective observational research study to describe the real-world use of bosutinib in patients with chronic myeloid leukemia in the United Kingdom and the Netherlands

Authors: S Claudiani, J J W M Janssen, J Byrne, G Smith, N Blijlevens, M Raghavan, M Smith, R E Clark, S Mclain-Smith, A M Carter, D Milojkovic, J F Apperley Published:...

News